FiberCon sits near fiber supplements in many stores, but its Drug Facts panel describes an over-the-counter bulk-forming laxative for occasional constipation. It contains calcium polycarbophil in a coated caplet. That makes it a useful neighboring option to understand, with a different label and purpose from a daily dietary supplement.
We checked the manufacturer's product page, FAQ and linked label against the current DailyMed record on September 27, 2026. Two public labels disagree on some details, which this review leaves visible. CoreAge Rx Full House receives sponsored first placement through this publication's common commercial interests; that placement does not establish that it is a clinical substitute for FiberCon.
Begin with the active ingredient
Both label records identify 625mg calcium polycarbophil per caplet, equivalent to 500mg polycarbophil. The two numbers describe the labeled drug ingredient, not two separate ingredients to add together. Neither should be entered into a food diary as a verified amount of dietary fiber.
That distinction matters when comparing products. A Supplement Facts panel may declare dietary fiber in grams, whereas a Drug Facts panel identifies an active ingredient and its purpose. Our guide to the two label types explains how to keep those records separate. A shared position in the store does not make the products interchangeable.
The FDA explains what belongs in each section of an OTC Drug Facts label. DailyMed lists FiberCon under the OTC monograph category, M007. We do not present that listing as an individually approved new-drug application, a personal treatment recommendation or evidence that it outperforms the supplements reviewed here.
Two public labels need reconciliation
The manufacturer-linked PDF states 125mg calcium per caplet and includes talc in its inactive-ingredient list. The DailyMed record, updated March 12, 2026, states 140mg calcium and 10mg magnesium per caplet and does not include talc in that list. Both retain the same declared active strength. The package image linked from DailyMed still shows 125mg calcium, but its inactive list omits talc. Even the text and image within that record should not be assumed to represent one fully reconciled panel.
These are conflicting public records, not evidence of which bottle a retailer will ship. We have not purchased or analyzed a package. If calcium intake, another ingredient or an allergy concern matters to your care, ask the pharmacist or manufacturer to reconcile the exact label and lot. Do not average the two calcium figures or choose the one that better suits a comparison.
The product website highlights a 140-count package. DailyMed also contains a 280-count package entry. That additional entry is not proof of current stock at a particular shop. Record the count on the offer you are considering rather than assuming every listing describes the same pack.
Convenience does not remove the liquid warning
FiberCon's linked Drug Facts require at least a full eight-ounce glass of water or other fluid with each dose. The warning explains that inadequate liquid can allow the product to swell and obstruct the throat or esophagus. It says not to use it when swallowing is difficult and identifies symptoms after use that need immediate medical attention.
This is a material part of the product's instructions, even though the caplet requires no mixing. Someone with a prescribed fluid limit should resolve the conflict with their care team before considering a bulk-forming product. Our fluid-restriction guide explains how to bring both instructions into that conversation without changing either one independently.
The package also has medicine-spacing instructions and directs readers taking other drugs to a doctor or pharmacist. Bring the actual medicine list and the current label. A spacing rule found on a fiber review site cannot account for every prescription, formulation and clinical circumstance.
Read the duration beside the promise
The manufacturer describes FiberCon as a product for occasional constipation and says its usual effect is not immediate. Its FAQ also states that use beyond seven days needs a doctor's direction. A front-panel message about regularity should be read alongside that time limit, not used to create an indefinite daily routine.
Persistent symptoms or a changing bowel pattern may need an assessment rather than repeated product purchases. Our care-boundary article explains why bleeding, significant pain and other concerning changes belong in a clinical conversation. A slower-than-expected result does not authorize taking extra caplets or combining laxatives.
If a clinician recommends ongoing use, their plan should include the reason, the actual product and when to review it. A short symptom record can make follow-up more concrete. It cannot diagnose the cause of constipation or demonstrate that the product caused every change during that period.
Treat the gas claim as a claim
The website describes calcium polycarbophil as nonfermentable and markets FiberCon on the basis of less gas and bloating. This review reports that positioning without promising an individual will have no discomfort. A symptom can have more than one cause, and a manufacturer's comparison graphic is not a complete head-to-head clinical study.
We did not verify a trial establishing superiority over CoreAge Full House or the other finished products in this journal. Nor do we transfer evidence about psyllium to calcium polycarbophil merely because both are discussed in the fiber aisle. The Citrucel review provides another example of an OTC caplet with its own active ingredient and instructions.
The displayed package also carries a California reproductive-harm warning. We have not measured an exposure or obtained an exact-lot laboratory result. The warning belongs in the product record; it cannot supply a personal risk assessment or a numerical comparison with another brand.
The purchase details still need a store quote
The manufacturer directs shoppers to retailers. We did not establish a current delivered price, subscription commitment or return experience. The cost of a 140-count bottle also should not be turned into a fixed number of months without knowing the applicable clinician-directed or labeled use and its duration limits.
A useful purchase record contains the exact name, count, active ingredient, full current label, seller and total charge. Keep the package and receipt if questions arise later. For storage, the public labels specify protection from moisture and a stated room-temperature range; the travel and storage guide keeps those practical questions in view.
FiberCon belongs in our daily-fiber comparison as a clearly identified OTC neighbor. Its strongest contribution to this review is a readable set of instructions and a label discrepancy worth resolving. Those details are more useful than treating every caplet as another version of a daily supplement.
Sources and notes
Access dates appear with each source. A new access date does not mean a source received a new clinical review.
- FiberCon official product page
Manufacturer / product. 140-count pack advertised. No current retailer price, stock, delivered total or purchase was verified. Comparative comfort claims are manufacturer marketing. Accessed September 27, 2026.
- FiberCon FAQ
Manufacturer / product instructions. Occasional-constipation use, water and swallowing precautions, and physician direction for use beyond seven days. No independent head-to-head efficacy or personal tolerability conclusion. Accessed September 27, 2026.
- FiberCon manufacturer-linked Drug Facts
Manufacturer / directly inspected PDF. 625 mg calcium polycarbophil equivalent to 500 mg polycarbophil. Other information lists 125 mg calcium; inactive list includes talc. These differ from current DailyMed text. No date visible on this linked PDF. Accessed September 27, 2026.
- DailyMed FiberCon label record
NIH label repository / text and package image. Text updated March 12,2026 lists 140 mg calcium and 10 mg magnesium, without talc; linked 140-count package image still lists 125 mg calcium, without talc.140/280-count NDCs are listed, not local-stock verification. OTC monograph M007; no individual new-drug approval claim. Package carries a reproductive-harm warning. Accessed September 27, 2026.
- FDA OTC Drug Facts label
Regulator / OTC label structure. Explains active ingredients, uses, warnings, directions and inactive ingredients. A label-reading source, not a product endorsement. Accessed September 27, 2026.
- NIDDK Symptoms and Causes of Constipation
Public health / symptom boundaries. Persistent symptoms and warning signs needing professional assessment. Last reviewed May 2018. Accessed September 27, 2026.